13:06 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP trial to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Zerbaxa was non-inferior to meropenem in...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
05:26 , Jan 19, 2018 |  BC Week In Review  |  Financial News

Vaccitech raises £20M series A

Vaccine company Vaccitech Ltd. (Oxford, U.K.) raised £20 million ($27.1 million) on Jan. 15 in a series A round co-led by new investors GV and Sequoia China and existing investor Oxford Sciences Innovation. New investor...
16:04 , Jan 15, 2018 |  BC Extra  |  Financial News

Vaccitech raises £20M series A

Vaccine company Vaccitech Ltd. (Oxford, U.K.) raised £20 million ($27.5 million) in a series A round co-led by new investors GV and Sequoia China and existing investor Oxford Sciences Innovation. New investor Neptune Ventures also...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Completed Phase IIb enrollment

BiondVax completed enrollment of 224 volunteers in a double-blind, Hungarian Phase IIb trial comparing intramuscular M-001 plus H5N1 influenza vaccine vs. H5N1 influenza vaccine alone. BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV), Ness Ziona, Israel...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: RNA transcripts nanoparticles (RNAtr NPs) for tumor-targeted siRNA delivery

Drug delivery TECHNOLOGY: Nanoparticles RNA transcripts nanoparticles (RNAtr NPs) could be used to deliver siRNA to folate receptor-expressing tumors. The nanoparticles consist of compact, tandem copies of synthetic siRNA hybridized to DNA-cholesterol, which promotes self-assembly, and to...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Additional Phase II data

An analysis of blood plasma samples from 120 elderly volunteers aged 65 and older who were treated 3 years ago in the double-blind, Israeli Phase II BVX-005 trial showed that >=50% of subjects who received...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Preliminary Phase II data

Preliminary data from the double-blind, placebo-controlled, Israeli Phase II BVX-006 trial in 36 volunteers ages 50-65 showed that 3 intramuscular injections of 1 mg M-001 every 21 days followed by an injection of the 2014/2015...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Cenderitide: Completed Phase II enrollment

Capricor completed enrollment of 14 patients in an open-label, dose-escalation, U.S. Phase II trial evaluating 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusion via Insulet’s OmniPod drug delivery system...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Cenderitide: Phase II started

Capricor began an open-label, dose-escalation, U.S. Phase II trial to evaluate 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet Drug Delivery System for up to 8 days...